Fig. 7: Hoxb13 functioned as a downstream effector of SUV-OE and regulated MA9 AML progression.
From: SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia

a H3K9me3 ChIP-qPCR analysis of Hoxb13 promoter in c-Kit+ cells from control and SUV-OE AML mice. Data are presented as the means ± s.e.m., n = 3, **P < 0.01, Student’s t test. b Quantitative RT-PCR analysis of Hoxb13 level in SUV-OE cells with Hoxb13-OE (MA9 + SUV + Hoxb13). Control cells were obtained in parallel with Hoxb13-OE cells (MA9 + SUV + mcherry). Data are presented as the means ± s.e.m., n = 3, ***P < 0.001, Student’s t test. c Kaplan–Meier survival curve of secondary recipients transplanted with leukemia cells; 1 × 103 cells per group, n = 6, **P < 0.01, Mantel–Cox test. d Colony-forming assay of MA9 + SUV + Hoxb13 and control cells from secondary recipients; n = 4, *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test. e qRT-PCR analysis of Hoxb13 level in normal murine HSPCs and leukemia stem cells from MLL-r leukemic mice. n = 3, *P < 0.05, **P < 0.01, Student’s t test. f Hoxb13 expression levels in MA9 AML cells with mock shRNA or shHoxb13 (knockdown). n = 3, ***P < 0.001, Student’s t test. g Number of colonies of MA9 AML cells with Hoxb13 knockdown (shHoxb13) or controls; n = 4, **P < 0.01, ***P < 0.001, Student’s t test. h Kaplan–Meier curves of secondary recipients transplanted with MA9-sh-scramble or with MA9-shHoxb13 cells, 33 days vs. 46 days, respectively; 1 × 104 cells for each group (n = 10 per group), **P < 0.01, Log-rank (Mantel–Cox) test.